ADMA Biologics Inc vs Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.18B), while Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 trades at $45.01. Which is the better fit depends on your goals.
| ADMA | USOI | |
|---|---|---|
Market Cap | $2.18B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $20.38 | $61.17 |
52-Week Low | $7.60 | $42.27 |
Enterprise Value | $2.25B | — |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
USOI (Credit Suisse X-Links Crude Oil Shares Covered Call ETN) trades at $45.05, up 0.2% with a bearish technical signal from moving averages. The ETN provides exposure to oil-linked covered call strategies, generating high yields but with complex risk exposure. Recent coverage highlights its unique structure and high yield potential amid shifting market dynamics.
The outlook remains cautious given the bearish technical setup and complex ETN structure. While the high yield strategy offers income potential, investors face significant commodity price volatility and counterparty risk. The lack of traditional equity fundamentals requires careful risk assessment of the underlying oil exposure and issuer creditworthiness.
Trailing returns across standard periods
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →USOI is an Exchange-Traded Note (ETN) issued by UBS that provides exposure to a covered call strategy on the United States Oil Fund (USO). It aims to generate high monthly income by capturing option premiums from the hypothetical sale of out-of-the-money call options on oil shares, offering a way to profit from crude oil's volatility even in a flat or range-bound market.
Read more on USOI →